Back

BioLineRx advances GLIX1 glioblastoma trial as third cohort starts in September

Verifying
  • BioLineRx reported progress in its Phase 1/2a GLIX1 trial for glioblastoma.
  • The second patient cohort is dosing, while the third cohort starts in September.
  • New preclinical data showed potent anti-tumor activity in a temozolomide-re... setting.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
BioLineRx advances GLIX1 glioblastoma trial as third cohort starts in September - CoinPost Terminal